Piramal Pharma (NSE:PPLPHARMA) Short-Term Debt: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:PPLPHARMA Piramal Pharma Ltd NSE:PPLPHARMA
50 GF Score
Price ₹206.64
GF Value ₹190.15
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Piramal Pharma Short-Term Debt?

Piramal Pharma NSE:PPLPHARMA -2.84% 50 Short-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:PPLPHARMA with a GF Score™ of 50/100 and a GF Value™ of ₹190.15 (Fairly Valued). The stock has 6 warning signs investors should review.

Piramal Pharma's Short-Term Debt for the quarter that ended in Jun. 2026 was ₹0 Mil.

Piramal Pharma's quarterly Short-Term Debt increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹11,955 Mil) but then declined from Mar. 2026 (₹11,955 Mil) to Jun. 2026 (₹0 Mil).

Piramal Pharma's annual Short-Term Debt declined from Mar. 2024 (₹20,751 Mil) to Mar. 2025 (₹15,062 Mil) and declined from Mar. 2025 (₹15,062 Mil) to Mar. 2026 (₹11,955 Mil).

Piramal Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Piramal Pharma Short-Term Debt Related Terms

Piramal Pharma Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Piramal Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Piramal Pharma Short-Term Debt Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Short-Term Debt
Get a 7-Day Free Trial 14,011.40 21,212.30 20,751.10 15,062.00 11,955.00

Piramal Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 13,985.90 0.00 11,955.00 0.00
NSE:PPLPHARMA
50GF Score
Piramal Pharma Ltd NSE:PPLPHARMA
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of ₹0 Mil mean?
Piramal Pharma (NSE:PPLPHARMA) has a Short-Term Debt of ₹0 Mil as of Jun. 2026.
Is Piramal Pharma's Short-Term Debt too high?
Piramal Pharma's current Short-Term Debt is ₹0 Mil. Overall, Piramal Pharma has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Piramal Pharma's Short-Term Debt compare to ZTS?
Piramal Pharma's Short-Term Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Drug Manufacturers company?
A good Short-Term Debt depends on the Drug Manufacturers industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Piramal Pharma's current Short-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Piramal Pharma stock overvalued right now?
Based on GuruFocus' analysis, Piramal Pharma (NSE:PPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹190.15, compared to a current price of ₹206.64 — trading 8.7% above its estimated fair value. The current Short-Term Debt is ₹0 Mil. Piramal Pharma's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Piramal Pharma (NSE:PPLPHARMA), the current Short-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Piramal Pharma (NSE:PPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Piramal Pharma stock appears to be overvalued. The current stock price of ₹206.64 is trading 8.7% above its estimated GF Value™ of ₹190.15. GuruFocus considers Piramal Pharma to be Fairly Valued.

Key valuation signals for NSE:PPLPHARMA:

  • Short-Term Debt: ₹0 Mil
  • GF Value™: ₹190.15 vs. price of ₹206.64 (8.7% above fair value)
  • GF Score™: 50/100 with 6 warning signs

No single metric tells the full story. See the NSE:PPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Piramal Pharma Business Description

Other Exchanges 543635:India
Address Kamani Junction, LBS Marg, Ground Floor, Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
50GF Score

Get the complete analysis for NSE:PPLPHARMA

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹206.64
Price
₹190.15
GF Value